MedPage Today news story<\/p>\n
Only one person has developed a new HIV infection during a year-long extension of the landmark PURPOSE 1 and PURPOSE 2 trials testing twice-yearly injectable lenacapavir (Yeztugo) for PrEP, according to twin open-label extensions.<\/p>\n
There were no new HIV cases in the PURPOSE 1 52-week open-label extension among adolescent girls and young women in South Africa and Uganda. That extension included 2,136 patients who remained on lenacapavir after the trial\u2019s randomized blinded phase ended, and 2,496 patients who switched at the extension\u2019s start to lenacapavir from either daily oral emtricitabine and tenofovir alafenamide (Descovy) or emtricitabine and tenofovir disoproxil fumarate (Truvada).<\/p>\n
The PURPOSE 2 52-week open-label extension saw only one new HIV infection among the cisgender men and transgender or gender-nonbinary persons who continued treatment. That new case was among the 1,587 patients who remained on lenacapavir; there were no new HIV cases among the 827 patients who switched from daily oral PrEP to lenacapavir.<\/p>\n
Read the full news story here<\/a>.<\/p>\n \/free registration is required\/<\/p>\n